529 related articles for article (PubMed ID: 17075601)
1. Interleukin 6: from bench to bedside.
Nishimoto N; Kishimoto T
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IL-6 for the treatment of inflammatory diseases.
Nishimoto N; Kishimoto T
Curr Opin Pharmacol; 2004 Aug; 4(4):386-91. PubMed ID: 15251133
[TBL] [Abstract][Full Text] [Related]
3. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
Murakami M; Nishimoto N
Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
Nishimoto N
Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
Nishimoto N
Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
[TBL] [Abstract][Full Text] [Related]
6. [Advances in interleukin-6 therapy].
Ogata A; Nishimoto N; Yoshizaki K
Rinsho Byori; 1999 Apr; 47(4):321-6. PubMed ID: 10340005
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic uses of anti-interleukin-6 receptor antibody.
Kang S; Tanaka T; Kishimoto T
Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
9. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
10. IL-6: from its discovery to clinical applications.
Kishimoto T
Int Immunol; 2010 May; 22(5):347-52. PubMed ID: 20410258
[TBL] [Abstract][Full Text] [Related]
11. [Anti-IL-6 receptor antibody].
Nishimoto N
Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
[No Abstract] [Full Text] [Related]
12. Clinical value of blocking IL-6 receptor.
Mima T; Nishimoto N
Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
[TBL] [Abstract][Full Text] [Related]
13. Technology evaluation: MRA, Chugai.
Ding C; Jones G
Curr Opin Mol Ther; 2003 Feb; 5(1):64-9. PubMed ID: 12669473
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6: discovery of a pleiotropic cytokine.
Kishimoto T
Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S2. PubMed ID: 16899106
[TBL] [Abstract][Full Text] [Related]
15. Cytokine signal regulation and autoimmune disorders.
Nishimoto N
Autoimmunity; 2005 Aug; 38(5):359-67. PubMed ID: 16227151
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 in rheumatoid arthritis.
Nishimoto N
Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
[TBL] [Abstract][Full Text] [Related]
17. The biology and medical implications of interleukin-6.
Tanaka T; Kishimoto T
Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
[TBL] [Abstract][Full Text] [Related]
18. The evidence for interleukin-6 as an autocrine growth factor in malignancy.
Akira S; Kishimoto T
Semin Cancer Biol; 1992 Feb; 3(1):17-26. PubMed ID: 1643291
[TBL] [Abstract][Full Text] [Related]
19. Is IL-1 a good therapeutic target in the treatment of arthritis?
Burger D; Dayer JM; Palmer G; Gabay C
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):879-96. PubMed ID: 16980212
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis.
Mircic M; Kavanaugh A
Exp Cell Res; 2011 May; 317(9):1286-92. PubMed ID: 21439276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
